BiotechTube

NBI-98854

Phase 3Completed
0 watching 0 views this week📈 Rising
74
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Tardive Dyskinesia

Conditions

Tardive Dyskinesia

Trial Timeline

Mar 1, 2015 → Mar 1, 2017

NCT ID
NCT02405091

About NBI-98854

NBI-98854 is a phase 3 stage product being developed by Neurocrine Biosciences for Tardive Dyskinesia. The current trial status is completed. This product is registered under clinical trial identifier NCT02405091. Target conditions include Tardive Dyskinesia.

Hype Score Breakdown

Clinical
27
Activity
18
Company
7
Novelty
9
Community
10

Clinical Trials (4)

NCT IDPhaseStatus
NCT03732534Phase 2Terminated
NCT02405091Phase 3Completed
NCT02256475Phase 1Completed
NCT01267188Phase 2Completed

Competing Products

13 competing products in Tardive Dyskinesia

See all competitors
ProductCompanyStageHype Score
SarizotanMerckPre-clinical
23
levetiracetam + placeboUCBPhase 3
74
ValbenazineNeurocrine BiosciencesPhase 1
30
Valbenazine Oral CapsuleNeurocrine BiosciencesApproved
82
NBI-98854 + NBI-98854 + PlaceboNeurocrine BiosciencesPhase 2
49
NBI-98854 + NBI-98854 + PlaceboNeurocrine BiosciencesPhase 2
49
Valbenazine + Placebo oral capsuleNeurocrine BiosciencesApproved
82
NBI-98854Neurocrine BiosciencesPhase 2
49
NBI-98854 + PlaceboNeurocrine BiosciencesPhase 3
74
ValbenazineNeurocrine BiosciencesPhase 3
74
NBI-98854 + NBI-98854 + PlaceboNeurocrine BiosciencesPhase 2
49
Valbenazine + Placebo oral capsuleNeurocrine BiosciencesApproved
82
NBI-1065890 + PlaceboNeurocrine BiosciencesPhase 2
49

Other Products from Neurocrine Biosciences

Valbenazine Oral CapsuleApproved
82
ValbenazineApproved
82
ValbenazineApproved
82
Valbenazine + Placebo oral capsuleApproved
82
Valbenazine + Placebo oral capsuleApproved
82